Issue 43, 2007

Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

Abstract

Copper(II)-diacetyl-bis(N4-methylthiosemicarbazone), Cu–ATSM, labeled with a positron emitting isotope of copper (60Cu, 61Cu, 62Cu or 64Cu) has been shown, in vitro and in vivo, to be selective for hypoxic tissue. In silico studies have explored the mechanism of its hypoxia selectivity, and clinical studies with this agent have shown non-invasive imaging data that is predictive of a cancer patients' response to conventional therapy. This Perspective discusses the evolution of Cu–ATSM, how its selectivity can be improved upon, and where this metal–ligand platform could be taken in the future.

Graphical abstract: Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

Article information

Article type
Perspective
Submitted
23 Apr 2007
Accepted
18 Jun 2007
First published
25 Sep 2007

Dalton Trans., 2007, 4893-4902

Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia

A. L. Vāvere and J. S. Lewis, Dalton Trans., 2007, 4893 DOI: 10.1039/B705989B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements